Dr Gough Au

Dr Gough Au

Conjoint Fellow

School of Biomedical Sciences and Pharmacy (Immunology and Microbiology)

Career Summary

Biography

Dr Gough Au is a conjoint Post Doctoral Research Fellow with the University of Newcastle and works for the Australian oncolytic virotherapy company Viralytics Ltd. Dr Au began his career as a NHMRC Industry Research fellow (2007-2011) carrying out research on the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma.

Research Expertise
Oncolytic virotherapy, Virology & Cancer Biology

Teaching Expertise
PHAR6124 Virology Lectures HUBS3204 Lab Professional Skills - Commercialisation of Science and Biotechnology Startup Companies.

Administrative Expertise
Animal Care and Ethics Committee member (2011- to present) Faculty of Health - Work Health and Safety Group.

Collaborations
Gough's main research interest is in the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma. Other interests include Oncolytic virotherapy, Virology and Cancer Biology.


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Carcinogenesis
  • Clinical sciences
  • Oncology
  • oncolytic virotherapy
  • virology

Fields of Research

Code Description Percentage
030499 Medicinal and Biomolecular Chemistry not elsewhere classified 35
111299 Oncology and Carcinogenesis not elsewhere classified 30
110399 Clinical Sciences not elsewhere classified 35

Professional Experience

Academic appointment

Dates Title Organisation / Department
1/05/2007 - 1/04/2011 Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/05/2007 -  NHMRC Industry Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/08/2004 - 1/05/2007 Research Director

Research Director/Post Doctoral Scientist

The University of Newcastle Research Associates
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (11 outputs)

Year Citation Altmetrics Link
2014 McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014) [C1]

© 2014 The Authors.Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed f... [more]

© 2014 The Authors.Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondrial DNA (mtDNA) under certain conditions, which is potently proinflammatory. We hypothesized that injury and orthopedic trauma surgery would induce NET production with mtDNA as a structural component. Methods: Neutrophils were isolated 8 trauma patients requiring orthopedic surgery postinjury and up to 5 days postoperatively. Four healthy volunteers provided positive and negative controls. Total hip replacement patients acted as an uninjured surgical control group. Neutrophil extracellular traps were visualized with DNA (Hoechst 33342TM/Sytox Green/MitoSox/MitoTracker) stains using live cell fluorescence microscopy with downstream quantitative polymerase chain reaction analysis of DNA composition. Results: Neutrophil extracellular traps were present after injury in all 8 trauma patients. They persisted for 5 days postoperatively. Delayed surgery resulted in NET resolution, but they reformed postoperatively. Total hip replacement patients developed NETs postoperatively, which resolved by day 5. Quantitative polymerase chain reaction analysis of NET-DNA composition revealed that NETs formed after injury and surgery were made of mtDNA with no detectable nuclear DNA component. Conclusions: Neutrophil extracellular traps formed after major trauma and subsequent surgery contain mtDNA and represent a novel marker of heightened innate immune activation. They could be considered when timing surgery after trauma to prevent systemic NET-induced inflammatory complications.

DOI 10.1016/j.jcrc.2014.07.013
Citations Scopus - 9Web of Science - 1
Co-authors Philip Hansbro, Zsolt Balogh, Douglas Smith
2013 Kok CC, Au GG, 'Novel marker for recombination in the 3'-untranslated region of members of the species Human enterovirus A', ARCHIVES OF VIROLOGY, 158 765-773 (2013) [C1]
DOI 10.1007/s00705-012-1533-2
Citations Scopus - 4Web of Science - 4
2011 Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
DOI 10.1186/1743-422x-8-22
Citations Scopus - 9Web of Science - 8
2009 Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
DOI 10.1007/s00109-008-0433-0
Citations Scopus - 8Web of Science - 6
2008 Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
DOI 10.1002/pros.20741
Citations Scopus - 13Web of Science - 12
2007 Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
DOI 10.1111/j.1365-2141.2007.06550.x
Citations Scopus - 25Web of Science - 21
Co-authors Lisa Lincz
2005 Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]
Citations Scopus - 33Web of Science - 35
2004 Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
DOI 10.1128/JVI.78.3.1431-1439.2004
Citations Scopus - 7Web of Science - 6
Co-authors Nicole Hansbro
2004 Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
DOI 10.1158/1078-0432.CCR-0690-3
Citations Scopus - 53Web of Science - 53
Co-authors Nicole Hansbro, Erin Harvey
2003 Newcombe NG, Andersson P, Johansson ES, Au GG, Lindberg AM, Barry RD, Shafren DR, 'Cellular receptor interactions of C-cluster human group A coxsackieviruses', JOURNAL OF GENERAL VIROLOGY, 84 3041-3050 (2003)
DOI 10.1099/vir.0.19329-0
Citations Scopus - 31Web of Science - 30
2000 Tooney PA, Au GG, Chahl LA, 'Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex', Neuroscience Letters, 283 185-188 (2000) [C1]
Citations Scopus - 35Web of Science - 37
Co-authors Paul Tooney
Show 8 more journal articles

Conference (12 outputs)

Year Citation Altmetrics Link
2015 Quay M, Wong Y, Au G, Shafren D, 'Immune-checkpoint blockade in combination with a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, significantly reduces tumor growth and tumor rechallenge', EUROPEAN JOURNAL OF CANCER (2015) [E3]
2014 Shafren D, Quah M, Wong Y, Andtbacka RH, Au G, 'Combination of a novel oncolyticimmunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model', Journal for ImmunoTherapy of Cancer (2014) [E3]
DOI 10.1186/2051-1426-2-S3-P125
2014 Simpson GR, Ajaz M, Launchbury FA, Bolton G, Melcher AA, Harrington KJ, et al., 'Major synergy between Coxsackievirus A21 (CAVATAK (TM)) and radiotherapy or chemotherapy in bladder cancer', HUMAN GENE THERAPY (2014) [E3]
2014 Wong YVY, Quah MY, Shafren DR, Au GG, 'Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)', HUMAN GENE THERAPY (2014) [E3]
2011 Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology (2011) [E3]
2011 Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research (2011) [E3]
DOI 10.1111/j.1755-148X.2011.00909.x
2011 Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology (2011) [E3]
2007 Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics (2007) [E3]
Co-authors Kathryn Skelding
2006 Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006 (2006) [E3]
Co-authors Kathryn Skelding
2005 Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting (2005) [E3]
Co-authors Kathryn Skelding
2005 Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting (2005) [E3]
Co-authors Kathryn Skelding
2000 Tooney PA, Au GG, Chahl LA, 'Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain', Proceedings of the Australian Physiological and Pharmacological Society Symposium Tachykinins: The Challenge Continues (2000) [E1]
Citations Scopus - 27Web of Science - 27
Co-authors Paul Tooney
Show 9 more conferences
Edit

Research Supervision

Number of supervisions

Completed3
Current2

Total current UON EFTSL

PhD0.95

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2014 PhD Investigation of Oncolytic CVA21 as a Potential Treatment for Pancreatic Cancer
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2012 PhD Investigating the Mechanisms of Tobacco Cigarette Smoke-Induced Lung Cancer
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2016 PhD Investigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2016 PhD Enhancement of Oncolytic Coxsackievirus A21 with Conventional Chemotherapies and Immune Checkpoint Inhibitors for the Treatment of Melanoma
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2014 PhD Low Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
Edit

Dr Gough Au

Position

Conjoint Fellow
Viralytics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Immunology and Microbiology

Contact Details

Email gough.au@newcastle.edu.au
Phone (02) 404 20253
Fax (02) 404 20027

Office

Room 2420
Building HMRI building
Location Level 2, HMRI Building East Wing

,
Edit